History-

The first developed technology platform with various application scenarios, including infectious disease, fertility, DOA, etc.

50+ kinds of reagents and five high-performance devices, focusing on detecting cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and others.

Single-dose Chemiluminescense Immunoassay Platform

Wondfo optical blood coagulation analyzer is the first one in the world that can test PT, APTT, TT, FIB, and ACT simultaneously.

Our Blood Gas Analyzer BGA-102 can produce the result in 30s. Its advantages of portability, easy operation, durability, and high performance make it ideal for clinics, laboratories, and hospitals.

Ready-to-use lyophilized RT-PCR Reagent；
Gold Standard for COVID-19 Diagnosis

Wondfo PA-3600 IHC Staining System

Colloidal Gold Platform

Immunofluorescence Platform

Chemiluminescence Platform

Coagulation Platform

Blood Gas Platform

Molecular Diagnostics Platform

Pathology Platform

Finecare™ Vitamin D, from complexity to simplicity

Building A World Free from Antibitoic Overuse

Advanced rapid diagnostic test with WHO prequalification for infectious disease

The Future Intelligent Medical Assistant to Healthcare

Fight against the pandemic through continuous innovation

New-generation Vitamin D

Wondfo CRP Campaign

International Public Health Solutions

1㎡ POCT Lab

COVID-19 Total Solution

Home/About us/Key Milestone

Wondfo Philosophy

Mission

Racing for Life

Vision

Advancing biotechnology to benefit society

Core Values

We strive to achieve our goals with passion to meet every customer's needs.
We respect every employee and provide opportunities for continuous self-improvement.
We dare to dream and take action to bring success to every partner.
We pursue excellence to safeguard everyone's health.

1992

Wondfo Biotech was founded.

1996

ENA Western Blotting Kit and Gold lmmunofiltration Assay ds-DNA Antibody Test Kit was available to public.

2001

Wondfo was accredited as a High-Tech Enterprise in China.

2003

Wondfo quickly responded to SARs and firstly developed SARS antigen test kit.

2007

Wondfo established the lmmunofluorescence Platform.

2009

Wondfo established a U.S.subsidiary.

2013

Wondfo developed H7N9 antigen test kit.

2015

Wondfo was listed on the Growth Enterprise Market of Shenzhen Stock Exchange.

2017

Wondfo won the State Science and Technology Progress Award.

2018

Wondfo received WHO PQ for HIV rapid test and launched chemiluminescence products.
Wondfo entered the veterinary diagnostics market and established a subsidiary, Wondko, focusing on veterinary diagnostics.

2020

Wondfo launched a complete "PCR+Antigen+Antibody" diagnostic solution for COVlD-19 became the first company in China to obtain certificates for COVlD-19 antigen and antibody tests, and released PocT molecular diagnostic products overseas for the first time.

2021

Wondfo launch the firts self-developed product in the Pathology Platform.

learn more

Have a Closer Look at Wondfo Wondfo Social Impact Research and Development

Choose your location